Pharmaceutical Technology on MSN18h
Opko and Entera focus on oral care for obesity and metabolic disorders
Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...
Nasdaq1d
OPKO Health and Entera Bio Collaborate to Advance Oral Dual Agonist Treatment for Metabolic Disorders
This new treatment combines OPKO's long-acting oxyntomodulin analog, OPK-88006, with Entera's N-Tab™ technology and shows promising data from preclinical studies. The companies plan to submit an ...